4DMedical (ASX:4DX) experienced a pullback of around 3.55 per cent at the time of writing on 10 August 2026, following an extraordinary period of gains that saw the medtech company emerge as one of the ASX's strongest performers. While short-term share-price movements can attract attention, the broader investment story centres on 4DMedical's respiratory-imaging technology, growing presence in the US healthcare market, reimbursement progress and potential to turn its technology platform into a scalable commercial business.

A different approach to lung imaging

4DMedical develops software designed to show how the lungs function, rather than simply providing an anatomical picture of the lungs.

Its technology can extract ventilation and perfusion information from medical imaging, including CT and X-ray scans. This provides clinicians with additional information about regional lung function and may help identify abnormalities that are not always apparent through conventional structural imaging alone.

The company's flagship technologies include CT:VQ and LDAf. These platforms are designed to work with imaging infrastructure that is already widely available in hospitals and diagnostic centres.

That approach is important commercially because it can reduce the need for highly specialised equipment and potentially make functional lung imaging more accessible to healthcare providers.

Targeting a large healthcare opportunity

Respiratory disease represents a substantial global healthcare burden, with conditions such as chronic obstructive pulmonary disease, asthma and other pulmonary disorders affecting millions of people.

4DMedical's technology is positioned around the idea that understanding lung function at a more detailed regional level could improve diagnosis, treatment planning and monitoring.

The technology may also have applications beyond routine clinical care. Functional lung imaging can potentially support pharmaceutical research and clinical trials by providing additional information about how patients respond to treatments.

This gives the company exposure to several potential markets rather than relying solely on conventional diagnostic imaging.

Growing presence in the United States

The United States has become a major focus of 4DMedical's commercial strategy.

In May 2026, the company announced a three-year contract with SimonMed Imaging to deploy its cardiopulmonary solutions across the US imaging provider's facilities. Such agreements are important because they provide a pathway from technological validation to actual clinical use.

The company has also made progress with Medicare reimbursement for non-contrast ventilation-perfusion imaging derived from routine chest CT scans.

Reimbursement is a particularly important milestone for medical-technology companies. Even when a technology receives regulatory approval, widespread adoption can remain limited if healthcare providers and patients do not have a clear pathway for reimbursement.

The development therefore potentially strengthens the commercial case for 4DMedical's technology.

Validation through major healthcare institutions

4DMedical has also built relationships and deployments involving recognised healthcare institutions.

Its technology has gained exposure through institutions including the Mayo Clinic, Stanford University and the Cleveland Clinic. The company has also partnered with pharmaceutical group GSK for applications involving clinical studies.

These relationships can provide more than commercial opportunities. They may also help demonstrate the usefulness of functional lung imaging to clinicians, researchers and potential customers.

For a growing medtech company, establishing credibility with major healthcare organisations can be an important step towards broader adoption.

Government and policy opportunities

Another potential growth avenue comes from the US government's interest in improving respiratory healthcare.

In July 2026, the AIR CARE for Veterans Act was introduced in the United States. The proposed legislation seeks to expand access to advanced functional lung imaging within federal healthcare programs and could potentially create opportunities involving the Department of Veterans Affairs.

For 4DMedical, developments of this nature could increase the potential addressable market for its technology.

However, legislative proposals should not be treated as guaranteed sources of future revenue. Their impact depends on the progress of legislation, implementation decisions and eventual healthcare adoption.

Revenue remains the key test

Despite the strong market enthusiasm surrounding 4DMedical, the company remains in an early stage of commercialisation.

The company reported first-half revenue of approximately A$2.85 million for the six months ended 31 December 2025. While the figure represents commercial activity, it remains small compared with the expectations embedded in the company's market valuation following its substantial share-price appreciation.

This creates an important distinction for investors.

The technology may have significant commercial potential, but that potential still needs to translate into sustained and rapidly growing revenue. Future results will therefore be important in determining whether contracts, reimbursement and deployments are developing into a scalable business model.

Strong cash position supports expansion

4DMedical entered this phase of expansion with a substantial cash position.

The company reported a pro-forma cash balance of approximately A$206.2 million following a January capital raising and option exercises.

A strong balance sheet gives the company greater flexibility as it invests in commercial expansion, clinical development, sales infrastructure and customer deployments.

It can also reduce the immediate need for additional capital raisings.

However, a large cash balance does not eliminate financial risk. Investors will still need to monitor the rate at which the company spends its capital and whether future revenue growth can eventually support the business without continued reliance on external funding.

The importance of commercial execution

The next stage of 4DMedical's development is likely to depend less on proving that its technology is interesting and more on demonstrating that it can be adopted at scale.

Hospital and imaging-network agreements need to translate into actual scan volumes. Reimbursement needs to generate increased clinical utilisation. Partnerships need to produce measurable commercial or research outcomes.

This transition from technology development to recurring revenue generation is often one of the most challenging phases for a medical-technology company.

Success could significantly expand the company's addressable market, while slower-than-expected adoption could place pressure on the investment case.

Risks investors should consider

Valuation is one of the most obvious risks following the company's substantial market re-rating.

When expectations for future growth become very high, even positive operational results may not be enough to support further gains if they fall short of what investors have already priced in.

Commercial execution is another major consideration. Securing contracts and reimbursement is important, but the company still needs to demonstrate consistent growth in revenue and customer utilisation.

There are also risks associated with the US healthcare system. Changes in reimbursement policies, healthcare regulation, government programs and institutional purchasing decisions can all influence adoption.

Competition is another factor. The medical-imaging industry includes established healthcare companies with substantial resources, and 4DMedical will need to demonstrate that its technology provides a sufficiently valuable clinical and economic benefit to secure long-term adoption.

What could shape the next phase

Several developments could influence 4DMedical's trajectory over the coming periods.

Revenue growth will be one of the clearest indicators of commercial progress. Investors will also be watching the rollout of the SimonMed relationship, additional hospital and imaging-network agreements and evidence of increasing utilisation following Medicare reimbursement developments.

Progress involving US government healthcare programs could provide another potential growth avenue.

At the same time, the company's cash position and expenditure will remain important indicators of financial discipline.

Ultimately, the company's ability to turn technological validation and market access into recurring revenue will determine whether its long-term opportunity can justify the expectations surrounding the business.

The bottom line

4DMedical has developed a differentiated approach to respiratory imaging that aims to provide clinicians with more information about how the lungs function.

Its growing US presence, Medicare reimbursement progress, relationships with major healthcare institutions, pharmaceutical partnerships and substantial cash position provide several potential avenues for expansion.

The opportunity is significant, but the company remains at an important transition point. The next phase will be about demonstrating commercial scale, converting partnerships and reimbursement access into recurring revenue, and maintaining disciplined capital management.

For investors, the longer-term story is therefore less about any individual day's share-price movement and more about whether 4DMedical can successfully establish functional lung imaging as a widely adopted component of modern respiratory healthcare.